€25.60
2.29% today
Xetra, Feb 28, 03:50 pm CET
ISIN
DE000A2P4LJ5
Symbol
PSG
Index
Sector
Industry

Pharmasgp Holding Stock price

€26.20
+0.20 0.77% 1M
+5.80 28.43% 6M
+1.20 4.80% YTD
+5.10 24.17% 1Y
+3.50 15.42% 3Y
-8.30 24.06% 5Y
-8.30 24.06% 10Y
Xetra, Closing price Thu, Feb 27 2025
+0.00 0.00%
ISIN
DE000A2P4LJ5
Symbol
PSG
Index
Sector
Industry

Key metrics

Market capitalization €314.14m
Enterprise Value €346.29m
P/E (TTM) P/E ratio 16.71
EV/FCF (TTM) EV/FCF 13.31
EV/Sales (TTM) EV/Sales 3.04
P/S ratio (TTM) P/S ratio 2.76
P/B ratio (TTM) P/B ratio 8.50
Dividend yield 5.19%
Last dividend (FY24) €1.36
Revenue growth (TTM) Revenue growth 16.86%
Revenue (TTM) Revenue €114.00m
EBIT (operating result TTM) EBIT €26.96m
Free Cash Flow (TTM) Free Cash Flow €26.01m
Cash position €37.77m
EPS (TTM) EPS €1.57
P/E forward 15.98
P/S forward 2.73
EV/Sales forward 3.01
Show more

Is Pharmasgp Holding a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,809 stocks worldwide.

Pharmasgp Holding Stock Analysis

Unlock Scores for Free

Analyst Opinions

1 Analyst has issued a forecast Pharmasgp Holding:

1x Buy
100%

Analyst Opinions

1 Analyst has issued a forecast Pharmasgp Holding:

Buy
100%

Financial data from Pharmasgp Holding

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Sep '24
+/-
%
114 114
17% 17%
100%
- Direct Costs 28 28
5% 5%
24%
86 86
21% 21%
76%
- Selling and Administrative Expenses 50 50
26% 26%
44%
- Research and Development Expense - -
-
-
36 36
16% 16%
32%
- Depreciation and Amortization 9.40 9.40
0% 0%
8%
EBIT (Operating Income) EBIT 27 27
23% 23%
24%
Net Profit 19 19
25% 25%
16%

In millions EUR.

Don't miss a Thing! We will send you all news about Pharmasgp Holding directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Pharmasgp Holding Stock News

EQS
4 months ago
Die Kernmarken des Unternehmens decken chronische Indikationen ab, darunter rheumatische Schmerzen und Nervenschmerzen sowie andere altersbedingte Leiden. In Deutschland ist PharmaSGP mit den Markenfamilien RubaXX® bei rheumatischen Schmerzen und Restaxil® bei neuralgischen Schmerzen (auch: Nerve...
EQS
4 months ago
Die Kernmarken des Unternehmens decken chronische Indikationen ab, darunter rheumatische Schmerzen und Nervenschmerzen sowie andere altersbedingte Leiden. In Deutschland ist PharmaSGP mit den Markenfamilien RubaXX® bei rheumatischen Schmerzen und Restaxil® bei neuralgischen Schmerzen (auch: Nerve...
EQS
4 months ago
Gräfelfing, den 05. November 2024 – Peter Gerckens, der dem Vorstand der PharmaSGP Holding SE seit 1. Juli 2024 als Chief Commercial Officer (CCO) angehört, wird zum 1. Januar 2025 die Position des Chief Executive Officer (CEO) des Unternehmens übernehmen. Dies hat der Aufsichtsrat heute beschlos...
More Pharmasgp Holding News

Company Profile

PharmaSGP Holding SE engages in the manufacture of non-chemical, over-the-counter pharmaceutical products. Its product brands include RubaXX, Restaxil, FULMINAN, DESEO, Neradin, and TAUMEA. The company is headquartered in Gräfelfing, Germany.

Head office Germany
CEO Peter Gerckens
Employees 89
Founded 2012
Website www.pharmasgp.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today